Pelthos: ZELSUVMI Momentum Shines Through a Convertible-Debt Restatement

Q2 net product revenue jumps 45% QoQ, but the quarter is shadowed by a fair-value restatement that leaves the commercial engine untouched.

PTHS · Earnings Call · 2026-08-13

Commercial Execution Keeps Accelerating

Pelthos Therapeutics (PTHS) delivered another strong quarter for its lead product ZELSUVMI, with net product revenue reaching $15.4M in Q2 2026, a 45% jump sequentially. Prescriptions rose 48% to 11,925 units, and the PBM contract signed late last year is clearly paying off: “Within this PBM, units dispensed increased 81.3% during the quarter, while the number of prescribers increased 68%.” — Sai Rangarao, Chief Commercial Officer · 2026-08-13 The company also noted that unique HCP prescribers surpassed 8,000, and new prescribers continue to come in at a rate of 150–200 per week. The pediatric segment, a key growth target, now represents 25–27% of prescribing, and management expects that to climb as the utilization of ZELSUVMI grows with back-to-school wellness visits. “We see an increased utilization of ZELSUVMI in that category. We're still hovering in that 25% to 27% range of pediatric utilization and prescribing of the product.” — Sai Rangarao, Chief Commercial Officer · 2026-08-13 This is a launch that is exceeding expectations, with more than 25,000 patients treated in the first full year.

The Accounting Overhang: A Restatement That Doesn't Touch the Business

The quarter's headline, however, is the restatement of Q1 2026 financials related to fair value accounting for convertible debt. The issue stems from a subordination agreement entered into in January 2026, which subordinated the convertible notes to new Horizon term loans. Management explained the misapplication of ASC 820 was purely a measurement issue, not an economic one.

The filing activity this morning associated with the first quarter of 2026 resulted from a misapplication of Accounting Standards Codification 820, Fair Value Measurements, related to certain fair value measurements used in estimating the fair value of our convertible debt, including valuation methodologies, specific valuation assumptions, and inputs.
John Gay, Chief Financial Officer · 2026-08-13

This is a subordination agreement that changed the face of the balance sheet, but as CFO John Gay stressed, "The restatement is limited to fair value accounting measurements... and does not affect the underlying economics of the company's convertible debt arrangements." “The restatement is limited to fair value accounting measurements associated with the company's convertible debt and related accounts and does not affect the underlying economics of the company's convertible debt arrangements.” — John Gay, Chief Financial Officer · 2026-08-13 The company has now filed the amended 10-Q and an 8-K, and the stock has traded up 13% over the past 90 days, suggesting investors are looking past the accounting noise.

Near-Term Outlook: Seasonality, Launches, and Cash Runway

Looking ahead, management remains confident in the trajectory. Gross-to-net (GTN) was a favorable 29.6% in Q2, and while they guide to mid-30s longer term, they noted that without an additional payer contract, they may stay in the low 30s. “In terms of claims relative to Q3, our early indicators tell us that it's actually going to be quite stable compared to where we are in Q2.” — Sai Rangarao, Chief Commercial Officer · 2026-08-13 That stability, combined with a doubling of refills quarter-over-quarter, supports a strong second half. The next catalysts are the launches of XEPI and Xeglyze, expected in Q1 and Q3 2027, respectively. These will leverage the existing sales territories and commercial infrastructure, requiring minimal incremental investment. Net income swung from a ~$1M quarterly loss in 2023 to a $10M loss in Q1 2026, reflecting the heavy investment behind ZELSUVMI's launch. With $24.2M in cash and an untapped $10M tranche from the Horizon facility, Pelthos believes it has sufficient runway to execute its plan. The convertible debt restatement, while messy, does not alter the commercial story, and the stock's recent recovery suggests the market agrees.